Javascript must be enabled to continue!
Evaluation of automated nucleic acid extraction devices for application in HCV NAT
View through CrossRef
BACKGROUND: To further improve the safety of the blood supply, various national blood transfusion organizations presently use or are in the process of implementing routine HCV NAT in minipools. According to the Committee for Proprietary Medicinal Products (CPMP) of the European Union, the HCV NAT detection limit of the assay should be 100 IU per mL (270 geq/mL) for testing initial plasma pools. Paul Ehrlich Institute (PEI) regulations stipulate that 5000 IU per mL (13,500 geq/mL) must be detected to calculate the amount contributed by individual donations composing the minipool. The sensitivity for HCV RNA extraction achieved by three commercially available laboratory kits was compared.STUDY DESIGN AND METHODS: Nucleic acids from 1‐in‐3 serial dilutions of an HCV RNA run control (Pelispy, CLB) were extracted with three kits (Cobas Amplicor, Roche Diagnostic Systems; BioRobot 9604, Qiagen; and NucliSens Extractor, Organon Teknika). HCV PCR of all extracts was performed using a second‐generation Cobas Amplicor HCV test and the Cobas Amplicor analyzer.RESULTS: The manual Cobas Amplicor, the BioRobot 9604, and the NucliSens Extractor setups allow a 95‐percent HCV RNA detection limit of 129, 82, and 12 geq per mL, respectively. The maximal pool size for the manual Cobas Amplicor, the BioRobot 9604, and the NucliSens Extractor kits that would still meet the PEI criteria for HCV NAT in minipools was calculated at 104, 164, and 1125 donations, respectively.CONCLUSION: All three HCV NAT kits evaluated meet the criteria set by CPMP and PEI. The highest sensitivity for HCV NAT screening can be achieved with the high‐volume NucliSens Extractor method in combination with the Cobas Amplicor HCV v2.0 test on the Cobas Amplicor analyzer.
Title: Evaluation of automated nucleic acid extraction devices for application in HCV NAT
Description:
BACKGROUND: To further improve the safety of the blood supply, various national blood transfusion organizations presently use or are in the process of implementing routine HCV NAT in minipools.
According to the Committee for Proprietary Medicinal Products (CPMP) of the European Union, the HCV NAT detection limit of the assay should be 100 IU per mL (270 geq/mL) for testing initial plasma pools.
Paul Ehrlich Institute (PEI) regulations stipulate that 5000 IU per mL (13,500 geq/mL) must be detected to calculate the amount contributed by individual donations composing the minipool.
The sensitivity for HCV RNA extraction achieved by three commercially available laboratory kits was compared.
STUDY DESIGN AND METHODS: Nucleic acids from 1‐in‐3 serial dilutions of an HCV RNA run control (Pelispy, CLB) were extracted with three kits (Cobas Amplicor, Roche Diagnostic Systems; BioRobot 9604, Qiagen; and NucliSens Extractor, Organon Teknika).
HCV PCR of all extracts was performed using a second‐generation Cobas Amplicor HCV test and the Cobas Amplicor analyzer.
RESULTS: The manual Cobas Amplicor, the BioRobot 9604, and the NucliSens Extractor setups allow a 95‐percent HCV RNA detection limit of 129, 82, and 12 geq per mL, respectively.
The maximal pool size for the manual Cobas Amplicor, the BioRobot 9604, and the NucliSens Extractor kits that would still meet the PEI criteria for HCV NAT in minipools was calculated at 104, 164, and 1125 donations, respectively.
CONCLUSION: All three HCV NAT kits evaluated meet the criteria set by CPMP and PEI.
The highest sensitivity for HCV NAT screening can be achieved with the high‐volume NucliSens Extractor method in combination with the Cobas Amplicor HCV v2.
0 test on the Cobas Amplicor analyzer.
Related Results
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
Hepatitis C virus (HCV) infection, which can cause chronic liver diseases, cirrhosis and hepatocellular carcinoma, is still a major public health problem worldwide. Upon comparing ...
Intrafamilial transmission of hepatitis C virus: a systematic review
Intrafamilial transmission of hepatitis C virus: a systematic review
To examine the risk of hepatitis C virus (HCV) transmission between patients infected with HCV and their household members (siblings, offspring and parents), as well as their stabl...
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
INFLUENCE OF HOST AND VIRAL FACTORS IN HEPATITIS C VIRUS INFECTION: ROLE OF TA REPEAT, IFNL3 AND IFNL4 POLYMORPHISMS IN HCV INFECTION AND OUTCOME OF TREATMENT
Hepatitis C virus (HCV) is a serious public health problem affecting 170 million carriers worldwide. It is a leading cause of chronic hepatitis, cirrhosis, and liver cancer and is ...
Comparative Analysis of Detection Efficacy Across Different Nucleic Acid Testing Modalities in Blood Centers
Comparative Analysis of Detection Efficacy Across Different Nucleic Acid Testing Modalities in Blood Centers
Abstract
Background and Objectives
Blood center Nucleic Acid Testing (NAT) laboratories primarily utilize Individual testing(ID...
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
INTRODUÇÃO: A detecção de HCV na triagem, em doadores de sangue da Fundação Hemopa, é realizada simultaneamente por um teste sorológico e um teste molecular. No caso de discordânci...
200. Rapid Initiation of Hepatitis C Treatment in Hospitalized Veterans Using a Real-Time Clinical Dashboard
200. Rapid Initiation of Hepatitis C Treatment in Hospitalized Veterans Using a Real-Time Clinical Dashboard
Abstract
Background
Over the last decade, the Veterans Health Administration (VHA) has treated and cured over 125,000 vet...
Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation
Provider Attitudes toward the Use of Hepatitis C Virus-Positive Organs in Kidney Transplantation
<b><i>Background:</i></b> Direct-acting antivirals have changed the landscape of hepatitis C virus (HCV) care. While transplantation with HCV-positive donor...
A comparative analysis between NAT and chemiluminescence in detection of transfusion transmitted viruses in two main university blood transfusion centers
A comparative analysis between NAT and chemiluminescence in detection of transfusion transmitted viruses in two main university blood transfusion centers
Abstract
Nucleic acid amplification Testing (NAT) is expected to minimize the potential risk of transfusion transmitted infections (TTIs) which escaped the detection by s...

